Table 3.
Patient characteristics based on appropriateness of dabigatran dosing in Group B.
| Patient characteristics | Appropriate dose n = 68 |
Inappropriate dose n = 32 |
p |
|---|---|---|---|
| Age (y), mean ± SD | 78 ± 7 | 65 ± 9 | <0.0001 |
| CrCl (mL/min), mean ± SD | 64 ± 25 | 89 ± 30 | 0.0012 |
| CHA2DS2-VASc, mean ± SD | 2 ± 1 | 1 ± 1 | <0.0001 |
| HAS-BLED score, mean ± SD | 1 ± 1 | 2 ± 1 | <0.0001 |
| Heart failure, % | 54.4 | 40.6 | 0.1984 |
| Hypertension, % | 85.2 | 75 | 0.21133 |
| Diabetes mellitus, % | 67.6 | 56.2 | 0.26803 |
| History of stroke, % | 35.2 | 3.1 | <0.001 |
| Peripheral arterial disease, % | 4.4 | 0.00 | 0.22766 |
| Gastrointestinal bleeding, % | 5.8 | 3.1 | 0.55508 |
| Use of antiplatelet drugs, % | 29.4 | 15.6 | 0.13749 |
CrCl = creatinine clearance; SD = standard deviation.